Novavax (NVAX) Cash Flow Statement

Click line-items for a historical chart and %

Operating Activities:
Net loss:	-222.86M
Reconciliation of net loss to net cash used in operating activities:
Change in fair value of warrant liability
Depreciation and amortization	6.29M
Amortization of net premiums on short-term investments	263K
Impairment of property and equipment
Deferred rent
Non-cash stock-based compensation	15.38M
Changes in operating assets and liabilities:
Accounts receivables	1.72M
Unbilled receivables
Prepaid expenses and other current assets	-2.48M
Accounts payable and accrued expenses	6.4M
Deferred revenue	-5.98M
Net cash used in operating activities
Investing Activities:
Capital expenditures	-15.01M
Proceeds from maturities of short-term investments	284.87M
Purchases of short-term investments
Net cash provided by (used in) by investing activities
Financing Activities:
Principal payments of notes payable	-350K
Net proceeds from sales of common stock, net of offering costs of $0.2 million and $0.1 million, respectively	0
Proceeds from the exercise of stock options	3.79M
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents	26.84M
Cash and cash equivalents at beginning of period	93.11M
Cash and cash equivalents at end of period	119.95M
Supplemental disclosure of non-cash activities:
Equipment purchases included in accounts payable	2.06M

Entities mentioned with NVAX